MX2021008851A - Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. - Google Patents

Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.

Info

Publication number
MX2021008851A
MX2021008851A MX2021008851A MX2021008851A MX2021008851A MX 2021008851 A MX2021008851 A MX 2021008851A MX 2021008851 A MX2021008851 A MX 2021008851A MX 2021008851 A MX2021008851 A MX 2021008851A MX 2021008851 A MX2021008851 A MX 2021008851A
Authority
MX
Mexico
Prior art keywords
depleting
antibodies
methods
red blood
blood cell
Prior art date
Application number
MX2021008851A
Other languages
English (en)
Inventor
Brendan Eckelman
John Timmer
Amir Razai
Quinn Deveraux
Kyle Jones
Mark Lappe
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/024995 external-priority patent/WO2013119714A1/en
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2021008851A publication Critical patent/MX2021008851A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Esta invención se relaciona generalmente a anticuerpos monoclonales que reconocen CD47, más específicamente a anticuerpos CD47 que no causan un nivel significativo de aglutinación de células, agotamiento de glóbulos rojos, anemia y/o agotamiento de plaquetas, a métodos para generar estos anticuerpos, y a métodos para usar estos anticuerpos monoclonales como agentes terapéuticos.
MX2021008851A 2013-02-06 2015-08-04 Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos. MX2021008851A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/024995 WO2013119714A1 (en) 2012-02-06 2013-02-06 Cd47 antibodies and methods of use thereof
US13/761,087 US9045541B2 (en) 2012-02-06 2013-02-06 CD47 antibodies and methods of use thereof
US201361815219P 2013-04-23 2013-04-23

Publications (1)

Publication Number Publication Date
MX2021008851A true MX2021008851A (es) 2021-09-08

Family

ID=51300031

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015010115A MX2015010115A (es) 2013-02-06 2013-08-06 Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.
MX2021008851A MX2021008851A (es) 2013-02-06 2015-08-04 Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015010115A MX2015010115A (es) 2013-02-06 2013-08-06 Anticuerpos cd47 de no agotamiento de plaquetas y no agotamiento de globulos rojos y metodos de uso de los mismos.

Country Status (20)

Country Link
EP (2) EP4137518A1 (es)
JP (2) JP2016507555A (es)
KR (2) KR102276974B1 (es)
CN (1) CN105101997B (es)
AU (2) AU2013377886B2 (es)
BR (1) BR112015018851A2 (es)
CA (1) CA2900468C (es)
CL (1) CL2015002203A1 (es)
EA (1) EA036963B1 (es)
ES (1) ES2944477T3 (es)
HK (1) HK1218863A1 (es)
IL (2) IL240390B (es)
MX (2) MX2015010115A (es)
NI (1) NI201500103A (es)
NZ (1) NZ710695A (es)
PE (1) PE20151408A1 (es)
PH (1) PH12015501729A1 (es)
SG (2) SG11201506132PA (es)
WO (1) WO2014123580A1 (es)
ZA (2) ZA201505745B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360772B (es) 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
AU2013362789B8 (en) 2012-12-17 2018-08-02 Pfizer Inc. Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions
ES2728066T3 (es) * 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CN107406503B (zh) * 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
BR112017014258A2 (pt) * 2014-12-30 2018-03-06 Celgene Corp anticorpos anti-cd47 e usos dos mesmos
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TW202248215A (zh) * 2015-03-04 2022-12-16 美商索倫多醫療公司 結合cd47之抗體治療劑
RU2748401C2 (ru) * 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
AU2016326423A1 (en) 2015-09-21 2018-04-26 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
KR20220163516A (ko) 2016-01-11 2022-12-09 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
US11472878B2 (en) * 2016-04-15 2022-10-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
US11649284B2 (en) 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
CN106084052B (zh) 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
WO2018009499A1 (en) 2016-07-06 2018-01-11 Celgene Corporation Antibodies with low immunogenicity and uses thereof
US10148939B2 (en) 2016-07-19 2018-12-04 Gopro, Inc. Mapping of spherical image data into rectangular faces for transport and decoding across networks
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2018081448A1 (en) 2016-10-26 2018-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
US11446315B2 (en) 2016-11-03 2022-09-20 Pf Argentum Ip Holdings Llc Enhancement of CD47 blockade therapy by proteasome inhibitors
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODIES
WO2018095428A1 (zh) * 2016-11-28 2018-05-31 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
JP7173971B2 (ja) 2016-12-09 2022-11-16 アレクトル エルエルシー 抗ＳＩＲＰ－α抗体及びその使用方法
CA3051512A1 (en) * 2017-01-26 2018-08-02 Zlip Holding Limited Cd47 antigen binding unit and uses thereof
CA3057139A1 (en) * 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
US11401329B2 (en) * 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
EP3706775A4 (en) 2017-11-06 2021-09-01 Trillium Therapeutics Inc. BLOCKING OF CD47 ASSOCIATED WITH RADIATION THERAPY
US20200347130A1 (en) * 2017-11-10 2020-11-05 Jiangsu Hengrui Medicine Co., Ltd. CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
EP3541941A4 (en) * 2017-11-10 2019-12-25 I-Mab Biopharma US Limited FUSION PROTEINS CONTAINING ANTI-CD47 ANTIBODIES AND CYTOKINES
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
TWI830774B (zh) * 2018-08-31 2024-02-01 大陸商南京聖和藥業股份有限公司 抗cd47抗體及其應用
WO2020047651A1 (en) 2018-09-04 2020-03-12 Trillium Therapeutics Inc. Cd47 blockade with parp inhibition for disease treatment
EP3826676A4 (en) * 2018-10-31 2022-05-04 I-Mab Biopharma US Limited NOVEL CD47 ANTIBODIES AND METHODS OF USE THEREOF
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
JP2023537331A (ja) * 2020-07-31 2023-08-31 バイオ－テラ ソリュ－ションズ，エルティーディー． Ｃｄ４７抗体及びその応用
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4050029A4 (en) * 2020-12-23 2023-07-12 Guangdong Feipeng Pharmaceutical Co., Ltd ANTIBODIES AGAINST CD47 AND USE THEREOF
CA3217814A1 (en) 2021-04-27 2022-11-03 Pfizer Inc. Enhancement of cd47 blockade therapy with dhfr inhibitors
WO2023073580A1 (en) 2021-10-29 2023-05-04 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69331089T2 (de) 1992-02-18 2002-07-18 Otsuka Kagaku Kk Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07508410A (ja) 1992-06-18 1995-09-21 ジェンファーム　インターナショナル　インコーポレイテッド 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU718138B2 (en) 1995-08-29 2000-04-06 Kyowa Hakko Kirin Co., Ltd. Chimeric animal and method for constructing the same
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2002315052A1 (en) * 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US8101719B2 (en) * 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
JP2011524741A (ja) 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
KR20160116056A (ko) * 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
HRP20221260T1 (hr) * 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
MX360772B (es) * 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Also Published As

Publication number Publication date
CA2900468A1 (en) 2014-08-14
EP4137518A1 (en) 2023-02-22
CA2900468C (en) 2024-04-30
WO2014123580A8 (en) 2015-10-22
BR112015018851A2 (pt) 2017-07-18
CL2015002203A1 (es) 2016-01-29
AU2013377886A1 (en) 2015-09-03
SG11201506132PA (en) 2015-09-29
EA201500818A1 (ru) 2016-02-29
KR20150123825A (ko) 2015-11-04
EP2953643A4 (en) 2016-11-09
ES2944477T3 (es) 2023-06-21
EP2953643A1 (en) 2015-12-16
WO2014123580A1 (en) 2014-08-14
EA036963B1 (ru) 2021-01-20
KR102170196B1 (ko) 2020-10-26
IL240390A0 (en) 2015-09-24
PE20151408A1 (es) 2015-10-15
MX2015010115A (es) 2016-05-31
KR20200123270A (ko) 2020-10-28
ZA201505745B (en) 2020-02-26
PH12015501729B1 (en) 2015-10-19
KR102276974B1 (ko) 2021-07-13
EP2953643B1 (en) 2023-02-22
ZA201905292B (en) 2022-09-28
AU2019200942B2 (en) 2021-01-21
IL274566B (en) 2021-10-31
JP2018177813A (ja) 2018-11-15
AU2013377886B2 (en) 2018-11-29
IL240390B (en) 2020-05-31
NZ710695A (en) 2020-05-29
AU2019200942A1 (en) 2019-02-28
JP2016507555A (ja) 2016-03-10
JP6726238B2 (ja) 2020-07-22
IL274566A (en) 2020-06-30
HK1218863A1 (zh) 2017-03-17
CN105101997B (zh) 2018-11-09
NI201500103A (es) 2016-09-29
SG10201706383XA (en) 2017-09-28
CN105101997A (zh) 2015-11-25
PH12015501729A1 (en) 2015-10-19

Similar Documents

Publication Publication Date Title
PH12015501729A1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
NZ741129A (en) Anti-pd1 antibodies and methods of use
EA201590528A1 (ru) Антитела к мсам и способы их применения
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
EA201492101A1 (ru) Антитела против fcrn
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX2019001355A (es) Anticuerpos monoclonales multiespecíficos.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2016011809A (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
MX2023006415A (es) Anticuerpos, usos y metodos.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
GB201207155D0 (en) Antibodies
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
CR20150449A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojosy métodos de uso de los mismos
NZ743971A (en) Antibodies to tau